Jump to content

Gp100:209-217(210M)

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 04:31, 1 July 2017 (→‎Clinical trials: HTTP→HTTPS for Reuters, per BRFA 8 using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Gp100:209-217(210M) is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210.[1] It is often referred to as the gp100 cancer vaccine which can also include other peptides based on gp100 (for example gp100:280-288(288V) [2][3]).

Clinical trials

It gave good results in a trial for advanced melanoma when used in combination with interleukin-2.[4]

Another trial against Ipilimumab in advanced melanoma suggested Ipilimumab may be better than the gp100 vaccine alone.[5]

References

  1. ^ http://www.cancer.gov/drugdictionary/?CdrID=476335
  2. ^ http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=492712
  3. ^ "Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma". 2010.
  4. ^ "Vaccine shows promise in advanced melanoma -study". Reuters. 30 May 2009.
  5. ^ http://www.genengnews.com/gen-news-highlights/bms-ipilimumab-proves-itself-in-metastatic-melanoma-patients/81243496/


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Gp100:209-217(210M)&oldid=788395271"